← Every company
Ligand Pharmaceuticals Inc SEC Filings
What Ligand Pharmaceuticals Inc has told the SEC happened, by the 8-K items and forms it filed under: when it reported results, who joined or left, what it bought or sold, and whether its auditor or its accounts ever changed.
LGND overview →Filings on file
156
since Nov 3, 2016
Warning signs
3
latest Apr 13, 2018
Last results
Aug 6, 2026
8-K item 2.02
Industry
Pharmaceutical Preparations
SIC 2834
Newest first
Each label is a form type or an 8-K item as filed; each row links to the filing.
| Filed | What it reports | Document |
|---|---|---|
| Jul 14, 2026 | Acquisition or sale completedMaterial agreementNew debt 8-K | Read ↗ |
| Jul 17, 2024 | Acquisition or sale completed 8-K | Read ↗ |
| Oct 18, 2023 | Acquisition or sale completedMaterial agreement 8-K | Read ↗ |
| Nov 4, 2022 | Executive or director changeAcquisition or sale completedMaterial agreement 8-K | Read ↗ |
| Oct 1, 2020 | Acquisition or sale completedMaterial agreement 8-K | Read ↗ |
| Aug 31, 2020 | Tender offer SC TO-T | Read ↗ |
| Mar 6, 2019 | Acquisition or sale completed 8-K | Read ↗ |
| Oct 10, 2018 | Acquisition or sale completed 8-K | Read ↗ |
Source: Ligand Pharmaceuticals Inc's EDGAR filing history, the last ten years. The labels are the form types and 8-K item numbers the company filed under, not a reading of what it wrote — an item 5.02 can be a chief executive fired or a director retiring on schedule — so each row links to the filing.